Tasly Pharmaceutical Group (SHA:600535), a unit of China Resources Pharmaceutical (HKG:3320), reported a 17% rise in net profit attributable to shareholders to 774.7 million yuan for the six months ended June 30, compared with 662.3 million yuan a year earlier, according to an Aug. 15 Hong Kong bourse filing.

Shares of Tasly rose nearly 7% in late-morning trade Monday.

Earnings per share came in at 0.52 yuan from 0.44 yuan a year earlier.

Revenue slipped nearly 2% to 4.29 billion yuan, compared with 4.37 billion yuan a year ago.